|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ovarian Neoplasms | |||||
| 2 | More general conditions related to this trial | ||||
| Adnexal Diseases | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Gonadal Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Ovarian Diseases | |||||
| Urogenital Neoplasms | |||||
| 3 | Interventions listed in this trial | ||||
| TLK286 HCl for injection | |||||
| doxorubicin HCl liposome injection | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Doxorubicin | |||||
| Topotecan | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antibiotics, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Telik | |||||